Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.38
20.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Revenue
Zhejiang Huahai Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
|
Revenue
¥9.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥10.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
¥10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥26B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥39.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥561.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhejiang Huahai Pharmaceutical Co Ltd
Glance View
Zhejiang Huahai Pharmaceutical Co., Ltd., nestled in the vibrant economic landscape of China, has crafted a reputation as a pioneering force in the pharmaceutical industry. The company began its journey with a modest ambition: to establish itself as a reliable provider of Active Pharmaceutical Ingredients (APIs). Over the years, Huahai has broadened its horizons beyond APIs, expanding into the realm of finished dosage forms. This strategic diversification has enabled the company to control the entire value chain—from manufacturing raw pharmaceutical compounds to delivering final medicines ready for consumption. This integrated approach not only enhances quality control but also fortifies their market presence globally, allowing Huahai to cement its status as a formidable player in pharmaceutical exports. What sets Zhejiang Huahai apart is its steadfast commitment to innovation and compliance with international standards. The company channels considerable resources into research and development, focusing on therapeutic areas such as cardiovascular and central nervous system disorders. This devotion to R&D not only fuels the pipeline of new products but also enhances profitability by ensuring a steady stream of high-demand medications. Furthermore, Huahai's strategic partnerships with global pharmaceutical giants shape a dual-edged strategy of market expansion and shared expertise. By working closely with partners worldwide, Huahai ensures that its products remain at the cutting edge of medical advancements while maintaining regulatory compliance in diverse markets. This approach is what powers Huahai's steady revenue growth and robust competitive edge in the ever-evolving pharmaceutical sector.
See Also
What is Zhejiang Huahai Pharmaceutical Co Ltd's Revenue?
Revenue
9.3B
CNY
Based on the financial report for Sep 30, 2024, Zhejiang Huahai Pharmaceutical Co Ltd's Revenue amounts to 9.3B CNY.
What is Zhejiang Huahai Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
15%
Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been 15% over the past three years , 12% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
